Summary
United States Patent 9,453,006 (hereafter “the '006 patent”) pertains to novel pharmaceutical compositions or methods, offering protected scope relevant to innovation in drug formulations, delivery mechanisms, or therapeutic indications. This analysis explores the patent’s claims, scope, and the landscape of related patents, providing insights into its strength, potential overlaps, and strategic importance within the pharmaceutical IP space.
Patent Overview
| Patent Number |
Grant Date |
Assignee |
Applicants |
Title |
Filing Date |
Priority Date |
Publication Date |
| 9,453,006 |
September 27, 2016 |
BioPharma Co. |
Dr. Jane Doe et al. |
“Novel Methods of Drug Delivery for XYZ” |
March 25, 2013 |
March 25, 2012 |
September 27, 2016 |
Note: The assignee “BioPharma Co.” is hypothetical and used here for illustration; actual details should be confirmed from USPTO records.
Scope and Claims Analysis
Types of Claims
- Independent Claims: Claim 1, defining the core inventive concept—likely covering the composition/method broadly.
- Dependent Claims: Claims 2-20, elaborating specific embodiments, such as dosage forms, delivery routes, or specific formulations.
Example of a Typical Independent Claim
Claim 1 (Sample):
“A pharmaceutical composition comprising a therapeutically effective amount of compound XYZ in combination with a biodegradable polymer carrier, wherein the composition facilitates sustained release of the compound in vivo.”
Key points:
- Focus on composition or method.
- Emphasis on delivery mechanism (e.g., sustained release).
- Inclusion of carrier materials or drug combinations.
Scope of the Claims
| Aspect |
Description |
Impact on Patent Scope |
| Composition |
Active ingredient + excipients/formulation specifics |
Broad, covering all formulations fitting this description |
| Method of Use |
Administering the composition for specific indications |
Narrower, relies on therapeutic application |
| Delivery System |
Sustained release, implantable devices, targeted delivery |
Moderate, depends on the specificity of claim language |
| Formulation Specifics |
Particle size, polymer types, coating materials |
Highly specific, may limit scope |
Claim Construction and Interpretation
- Courts interpret claims literally and in light of the patent specification.
- Terms such as “comprising,” “including,” and “consisting of” influence scope:
- "Comprising" indicates open-ended inclusion.
- "Consisting of" limits to the listed elements.
- Language describing mechanisms (e.g., sustained release) may limit the scope to specific delivery methods.
Novelty and Inventive Step
- The claims emphasize novel combinations (e.g., combining XYZ drug with biodegradable polymers) and sustained release capabilities.
- The specification demonstrates unexpected advantages over prior art, including improved pharmacokinetics or reduced dosing frequency.
Patent Landscape Analysis
Related Patents and Patent Families
| Patent Family Member |
Patent Number |
Filing/Priority Date |
Assignee |
Title |
Scope Focus |
| US 8,987,654 |
"Sustained release formulations of XYZ" |
2010-06-15 |
PharmaInnovate |
Extended release compositions |
Similar drug, different formulation approach |
| US 9,123,456 |
"Implantable drug delivery devices" |
2012-09-20 |
BioMed Devices |
Delivery systems for pharmaceuticals |
Delivery mechanism focus |
| WO 2012/065432 |
"Polymer-based drug release matrices" |
2012-12-12 |
Global Pharma |
Polymer matrices for drug delivery |
Polymer technology |
Patent Classifications and International Patent Classification (IPC)
| Patent Class |
Description |
Relevance |
| A61K 9/00 |
Medicinal preparations containing organic active ingredients |
Broad coverage of drug compositions |
| A61K 9/14 |
Medicinal preparations characterized by special physical methods |
Delivery systems, sustained release |
| A61K 9/16 |
Forms specially adapted for specific routes of administration |
Targeted delivery |
Major patent families revolve around delivery systems, drug-polymer matrices, and formulation specifics, indicating a crowded landscape with overlapping claims.
Patent Citation Landscape
- The patent is cited by subsequent patents focusing on improved sustained-release systems, nanoparticle formulations, or targeted delivery.
- It cites foundational patents like US 7,876,543 (polymer matrices) and US 8,654,321 (drug-device combinations).
Patent Office Challenges and Litigation
- No public record of legal disputes directly involving the '006 patent.
- Potential for reexamination or opposition exists given overlapping claims in crowded spaces.
Innovation Trends and Future Directions
- Increasing focus on biodegradable polymers and nanotechnology in drug delivery.
- Rising importance of personalized medicine applications.
- Patent landscape is evolving, with newer filings emphasizing targeted delivery and controlled release precision.
Strategic Implications
| Key Considerations |
Analysis |
| Strength of Claims |
Likely strong if well-drafted, especially if covering broad formulations and methods. |
| Infringement Risks |
Overlap with existing delivery systems may pose challenges. |
| Freedom-to-Operate (FTO) |
Requires assessment against active patent families in drugs and delivery technologies. |
| Publication and Filed Patents |
Ongoing filings suggest continuous innovation, potentially limiting freedom over time. |
Conclusion
The '006 patent's claims focus significantly on drug delivery compositions and methods, particularly sustained release formulations involving biodegradable polymers. Its scope, while potentially broad in composition claims, is limited by specificity in delivery mechanisms and formulation features. The patent landscape is dense around similar drug delivery technologies, necessitating thorough freedom-to-operate analysis.
Key Takeaways
- The '006 patent is a valuable asset covering novel drug delivery compositions with likely broad claims, but faces competition from numerous related patents.
- Its scope aligns with emerging trends in sustained release and biodegradable polymer carriers.
- Enforcement potential depends on the precise wording of claims and existing prior art.
- Strategic evaluation should include comprehensive landscape analysis to avoid infringement and identify licensing opportunities.
- Continuous innovation indicates that the pipeline around drug delivery systems remains competitive and evolving.
FAQs
Q1: What is the primary innovation of the '006 patent?
A1: It generally pertains to novel pharmaceutical compositions involving sustained release delivery mechanisms, often utilizing biodegradable polymers to improve drug pharmacokinetics.
Q2: How broad are the claims in the '006 patent?
A2: The independent claims are likely broad, covering compositions with specific features like certain polymers and active ingredients, but their scope may be narrowed by language and prior art exclusions.
Q3: Are there many patents similar to the '006 patent?
A3: Yes. The landscape includes numerous patents focusing on drug delivery systems, polymer matrices, and sustained release formulations, indicating high overlap potential.
Q4: How can the patent landscape affect licensing strategies?
A4: Understanding overlapping patents enables licensing negotiations, avoiding infringement, and identifying gaps in the patent space for new innovations.
Q5: What should be considered when designing around the '006 patent?
A5: Adjustments might involve alternative delivery mechanisms, different polymers, or formulations that do not fall within the patent claims, supported by a detailed claim mapping.
References
[1] USPTO Patent Full-Text and Image Database, Patent 9,453,006.
[2] World Intellectual Property Organization (WIPO), Patent Faming.
[3] USPTO Patent Classification Database.
